Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (DE:MMQ)
FRANKFURT:MMQ
MMQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.29 - €9.80
Previous CloseN/A
Volume187.00
Average Volume (3M)198.00
Market Cap
$427.12M
Enterprise Value€332.28M
Total Cash (Recent Filing)$29.54K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
May 08, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding75,368,360
10 Day Avg. Volume30
30 Day Avg. Volume198
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.14
Forecast
1Y Price Target
$20.47Price Target Upside285.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Mind Medicine News
PremiumCompany Announcements
MindMed to Announce Q1 2025 Financial Results
PremiumCompany Announcements
MindMed Issues Inducement Grants to New Employees
PremiumCompany Announcements
MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder
PremiumCompany Announcements
MindMed Advances Clinical Programs with Strong Financial Backing
PremiumCompany Announcements
MindMed Appoints New CCO to Drive Commercial Strategy for MM120 Launch
PremiumCompany Announcements
MindMed Issues Inducement Grants to New Employees---
Bulls Say, Bears Say
Bulls Say
Earnings PotentialThe stock is viewed as significantly undervalued given the unmet need in and large sizes of the GAD/MDD markets.
Financial PositionWith $274M in cash, MindMed is well-capitalized to execute on the program and prepare for commercialization, with a focus on payer engagement, market access, and interventional psychiatry integration.
Regulatory ProgressMindMed announced it has secured alignment with the FDA, including a reduction in required treatment session duration to 8 hours, which strengthens the feasibility of MM120 as a commercial therapy.
Bears Say
Clinical TrialsThe MMED008 data demonstrated statistically significant and clinically meaningful reductions in anxiety symptoms compared to placebo.
Development RisksThe emerging psychedelics space has clear FDA guidance for regulatory approval, which is a positive signal for Mind Medicine Inc.
Market CompetitionMM120's potential to rapidly reduce depressive symptoms could make it a compelling alternative to ketamine-based treatments, which require repeated administrations.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.76% Insiders
5.22%
Mutual Funds
0.17% Other Institutional Investors
84.10% Public Companies and
Individual Investors
MMQ FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was €4.29 and its highest was €9.80 in the past 12 months.
What is Mind Medicine’s market cap?
Mind Medicine’s market cap is $427.12M.
When is Mind Medicine’s upcoming earnings report date?
Mind Medicine’s upcoming earnings report date is May 08, 2025 which is in 13 days.
How were Mind Medicine’s earnings last quarter?
Mind Medicine released its earnings results on Mar 06, 2025. The company reported -€0.361 earnings per share for the quarter, missing the consensus estimate of -€0.258 by -€0.103.
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate is -0.32.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 75,368,360 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Mind Medicine reported an EPS of -€0.361 in its last earnings report, missing expectations of -€0.258. Following the earnings report the stock price went up 1.121%.
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in DE:MMQ
---
Mind Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.47 (285.41% Upside)
$20.47 (285.41% Upside)
Blogger Sentiment
Bullish
DE:MMQ Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $17.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.99%
12-Months-Change
Fundamentals
Return on Equity
-68.01%
Trailing 12-Months
Asset Growth
142.61%
Trailing 12-Months
Company Description
Mind Medicine
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
---
MMQ Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted MindMed's strong financial position and progress towards Phase III trials, while also acknowledging rising R&D expenses and a net loss. The sentiment leans towards positive due to the company's strong cash reserves and clear roadmap for advancing clinical trials.Read More>---
MMQ Stock 12 Month Forecast
Average Price Target
€20.47
▲(285.41% Upside)
Technical Analysis
Best Analysts Covering MMQ
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+25.01%
reiterated a buy rating 10 days ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +25.01% per trade.
---